Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled ascending-dose study of AB521 in healthy volunteers
NL-OMON51736Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of casdatifan in renal cell carcinoma (RCC) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Safety and tolerability of AB521 after single and multiple oral doses and Pharmacokinetic profile of AB521. Started Nov 2021; status: completed.
02
Drugs
casdatifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON51736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51736.